“NQO1 Gene C609T Polymorphism (dbSNP: rs1800566) and Digestive Tract Cancer Risk: A Meta-Analysis.”

References

• Parkin DM, Bray F, Ferlay J, and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108, 2005. doi:10.3322/canjclin.55.2.74.
   PubMed Web of Science ®Google Scholar
• Kanavos P: The rising burden of cancer in the developing world. Ann Oncol 17, 15–23, 2006. doi:10.1093/annonc/mdl983.
   Web of Science ®Google Scholar
• Enzinger PC, and Mayer RJ: Esophageal cancer. N Engl J Med 349, 2241–2252, 2003. doi:10.1056/NEJMra035010.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12), 2893–2917, 2010. doi:10.1002/ijc.25516.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al.: Global cancer statistics. CA Cancer J Clin 61(2), 69–90, 2011. doi:10.3322/caac.20107.
   PubMed Web of Science ®Google Scholar
• Zhu CL, Huang Q, Liu CH, Lin XS, Xie F, et al.: NAD(P)H: quinoneoxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: a meta-analysis. Asian Pac J Cancer Prev 14(4), 2349–2354, 2013. doi:10.7314/APJCP.2013.14.4.2349.
   PubMedGoogle Scholar
• Compare D, Rocco A, and Nardone G: Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 14, 302–308, 2010.
   PubMed Web of Science ®Google Scholar
• Mandal RK, Nissar K, and Mittal RD: Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol Biol Rep 39(12), 11145–11152, 2012.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, and Talalay P: NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 501(1), 116–123, 2010. doi:10.1016/j.abb.2010.03.019.
   PubMed Web of Science ®Google Scholar
• Siegel D, McGuinness SM, Winski SL, and Ross D: Genotype–phenotype relationships in studies of a polymorphism in NAD(P)H:quinoneoxidoreductase 1. Pharmacogenetics 9, 113–121, 1999. doi:10.1097/00008571-199902000-00015.
   PubMedGoogle Scholar
• Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, et al.: Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 58(5), 1146–1155, 2000.
   PubMed Web of Science ®Google Scholar
• Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, et al.: Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 21(5), 1119–1124, 2002.
   PubMed Web of Science ®Google Scholar
• Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, Van't Veer LJ, et al.: ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC Cancer 8(105), 2008.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Roe AL, Vandale SE, Bingham E, and Oakley GG: NAD(P)H: quinoneoxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 4, 62–70, 2002. doi:10.1097/00125817-200203000-00003.
   PubMed Web of Science ®Google Scholar
• Kuehl BL, Paterson JW, Peacock JW, Paterson MC, and Rauth AM: Presence of a heterozygous substitution and its relationship to DT diaphorase activity. Br J Cancer 72, 555–561, 1995. doi:10.1038/bjc.1995.373.
   PubMed Web of Science ®Google Scholar
• Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, et al.: Characterization of a polymorphism in NAD(P)H: quinoneoxidoreductase (DT-diaphorase). Br J Cancer 75(1), 69–75, 1997. doi:10.1038/bjc.1997.11.
   PubMed Web of Science ®Google Scholar
• Moran JL, Siegel D, and Ross D: A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H quinoneoxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 96, 8150–8155, 1999. doi:10.1073/pnas.96.14.8150.
   PubMed Web of Science ®Google Scholar
• Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, et al.: Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinoneoxidoreductase 1. Mol Pharmacol 59(2), 263–268, 2001.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Li Y, Wang R, Geddert H, Guo W, et al.: NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol 9, 1390–1393, 2003. doi:10.3748/wjg.v9.i7.1390.
   PubMed Web of Science ®Google Scholar
• Malik MA, Zargar SA, and Mittal B: Role of NQO1 609C >T and NQO2-3423G >A polymorphisms in susceptibility to gastric cancer in Kashmir Valley. DNA Cell Biol 30, 297–303, 2011. doi:10.1089/dna.2010.1115.
   PubMed Web of Science ®Google Scholar
• Zhang J, Schulz WA, Li Y, Wang R, Zotz R, et al.: Association of NAD(P)H: quinoneoxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 24, 905–909, 2003. doi:10.1093/carcin/bgg019.
   PubMed Web of Science ®Google Scholar
• Malik MA, Zargar SA, and Mittal B: Role of NQO1 609C>T and NQO2-3423 G>A gene polymorphisms in esophageal cancer risk in Kashmir Valley and meta-analysis. Mol Biol Rep 39, 9095–9104, 2012.
   PubMed Web of Science ®Google Scholar
• Umar M, Upadhyay R, Kumar S, Ghoshal UC, and Mittal B: Null association of NQO1 609C>T and NQO2-3423G>A polymorphisms with susceptibility and prognosis of esophageal cancer in north Indian population and meta-analysis. Cancer Epidemiol 36, e373–e379, 2012. doi:10.1016/j.canep.2012.06.004.
   PubMed Web of Science ®Google Scholar
• Yin J, Wang L, Wang X, Zheng L, Shi Y, et al.: NQO1 rs1800566 C>T polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Scand J Gastroenterol 49(3), 317–322, 2014. doi:10.3109/00365521.2013.873819.
   PubMed Web of Science ®Google Scholar
• Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, et al.: Association between NAD(P)H: quinoneoxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 107, 381–386, 2003. doi:10.1002/ijc.11430.
   PubMed Web of Science ®Google Scholar
• Chen DJ, Ding R, Cao W, and Ye DQ: Interaction between polymorphisms in NQO1(C609T) and XRCC1(G28152A) and their correlation with smoking on gastric cancer. Zhonghua Liu Xing Bing XueZaZhi 32(1), 5–8, 2011.
   PubMedGoogle Scholar
• Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, et al.: NAD(P)H: quinoneoxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7, 103–108, 2002.
   PubMedGoogle Scholar
• Hu WG, Hu JJ, Cai W, Zheng MH, Zang L, et al.: The NAD(P)H: quinine oxidoreductase 1 (NQO1) gene 609 C>T polymorphism is associated with gastric cancer risk: evidence from a case-control study and a meta-analysis. Asian Pac J Cancer Prev 15(5), 2363–2367, 2014. doi:10.7314/APJCP.2014.15.5.2363.
   PubMedGoogle Scholar
• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al.: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15), 2008–2012, 2000. doi:10.1001/jama.283.15.2008.
   PubMed Web of Science ®Google Scholar
• Guo J, Jin M, Zhang M, and Chen LA: Genetic variant in miR-196a2 increased digestive system cancer risks: a meat-analysis of 15 case-control studies. PLoS ONE 7(1), e30585, 2012. doi:10.1371/journal.pone.0030585.
   PubMed Web of Science ®Google Scholar
• Cochran WG: The combination of estimates from different experiments. Biometrics 10, 101–129, 1954. doi:10.2307/3001666.
   Web of Science ®Google Scholar
• Higgins JP, and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539–1558, 2002. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Mantel N, and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719–748, 1959.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, and Laird N: Meta-analysis in clinical trials. Control Clin Trials 7, 177–188, 1986. doi:10.1016/0197-2456(86)90046-2.
   PubMed Web of Science ®Google Scholar
• Begg CB, and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101, 1994. doi:10.2307/2533446.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634, 1997. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, et al.: Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Software 49, 1–15, 2013.
   Web of Science ®Google Scholar
• Bax L, Yu LM, Ikeda N, Tsuruta H, and Moons KG: Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 6, 50, 2006.
   PubMed Web of Science ®Google Scholar
• Harth V, Donat S, Ko Y, Abel J, Vetter H, et al.: NAD(P)H quinoneoxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 73(10–11), 528–531, 2000. doi:10.1007/s002040050004.
   PubMed Web of Science ®Google Scholar
• Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, et al.: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23, 1839–1849, 2002. doi:10.1093/carcin/23.11.1839.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang JH, Guo W, Wang R, Wen DK, et al.: Association between NAD(P)H: quinoneoxidoreductase 1 C609T polymorphism and cancer of gastric cardia risk. Zhonghua Liu Xing Bing XueZaZhi 25, 731, 2004.
   PubMedGoogle Scholar
• Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, et al.: CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis 26, 1122–1128, 2005. doi:10.1093/carcin/bgi054.
   PubMed Web of Science ®Google Scholar
• von Rah den BH, Stein HJ, Langer R, von Weyhern CW, Schenk E, et al.: C609T polymorphism of the NAD(P)H:quinoneoxidoreductase I gene does not significantly affect susceptibility for esophageal adenocarcinoma. Int J Cancer 113, 506–508, 2005. doi:10.1002/ijc.20576.
   PubMed Web of Science ®Google Scholar
• Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, and Bird RP: A NAD(P)H:quinoneoxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev 15(12), 2422–2426, 2006. doi:10.1158/1055-9965.EPI-06-0661.
   PubMed Web of Science ®Google Scholar
• Ren JJ, Ouyang XH, and Su XL: NAD(P)H: quinoneoxidoreductase gene polymorphism association with gastric carcinoma. ZhonghuaZhong Liu Fang ZhiZaZhi 11, 1686–1688, 2006.
   Google Scholar
• van der Logt EM, Bergevoet SM, Roelofs HM, TeMorsche RH, Dijk Y, et al.: Role of epoxide hydrolase, NAD(P)H:quinoneoxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 593, 39–49, 2006. doi:10.1016/j.mrfmmm.2005.06.018.
   PubMed Web of Science ®Google Scholar
• Zhang WC, Yin LH, Pu YP, Liang GY, Hu X, et al.: Relationship between quinone oxidoreductase1 gene ns-cSNP and genetic susceptibility of esophageal cancer. Zhonghua Yu Fang Yi XueZaZhi 40, 324–327, 2006.
   PubMedGoogle Scholar
• Chen D, Chi Y, Yu Q, Wang S, Ye D: Interaction of polymorphisms of NQO1 and environmental risk factors in gastric cancer. Acta Univ Medicinalis Anhui 42, 405–408, 2007.
   Google Scholar
• di Martino E, Hardie LJ, Wild CP, Gong YY, Olliver JR, et al.: The NAD(P)H:quinoneoxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med 9, 341–347, 2007. doi:10.1097/GIM.0b013e3180654ccd.
   PubMed Web of Science ®Google Scholar
• Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, et al.: Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis 28, 875–882, 2007. doi:10.1093/carcin/bgl194.
   PubMed Web of Science ®Google Scholar
• Feng X, Li Z, Wang L, Zhang J, and Lu Z: Study on the relationship between polymorphisms of NQO1 gene and susceptibility to esophageal cancer. Chinese J Dis Control Prev 12, 112–114, 2008.
   Google Scholar
• Tijhuis MJ, Visker MH, Aarts JM, Laan W, de Boer SY, et al.: NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int J Cancer 122, 1842–1848, 2008. doi:10.1002/ijc.23246.
   PubMed Web of Science ®Google Scholar
• Zhou YL, Chen HF, Shi XS, Zhou ZX, Li GL, et al.: A case–control study on the polymorphisms of NQO1 and susceptibility of esophageal cancer. Bulletin Chinese Cancer 15, 659–663, 2006.
   Google Scholar
• Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, et al.: Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 24, 1347–1353, 2010.
   PubMed Web of Science ®Google Scholar
• Nisa H, Kono S, Yin G, Toyomura K, Nagano J, et al.: Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. BMC Cancer 10, 274, 2010.
   PubMed Web of Science ®Google Scholar
• Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, et al.: Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 20, 315–326, 2010. doi:10.1097/FPC.0b013e3283395c6a.
   PubMed Web of Science ®Google Scholar
• Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, et al.: NAD(P)H:quinoneoxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac J Cancer Prev 11, 209–213, 2010.
   PubMedGoogle Scholar
• Marjani HA, Biramijamal F, Rakhshani N, Hossein-Nezhad A, and Malekzadeh R: Investigation of NQO1 genetic polymorphism, NQO1 gene expression and PAH-DNA adducts in ESCC. A case-control study from Iran. Genet Mol Res 9, 239–249, 2010. doi:10.4238/vol9-1gmr693.
   PubMed Web of Science ®Google Scholar
• Su XL, Yan MR, Yang L, and Qimuge-Suyila: NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia. Chin J Cancer Res 24(4), 317–322, 2012. doi:10.1007/s11670-012-0270-0.
   PubMed Web of Science ®Google Scholar
• Hamachi T, Tajima O, Uezono K, Tabata S, Abe H, et al.: CYP1A1, GSTM1, GSTT1 and NQO1 polymorphisms and colorectal adenomas in Japanese men. World J Gastroenterol 19(25), 4023–4030, 2013. doi:10.3748/wjg.v19.i25.4023.
   PubMed Web of Science ®Google Scholar
• Peng XE, Jiang YY, Shi XS, and Hu ZJ: NQO1 609C>T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population. Gene 521(1), 105–110, 2013. doi:10.1016/j.gene.2013.02.029.
   PubMed Web of Science ®Google Scholar
• Freriksen JJ, Salomon J, Roelofs HM, TeMorsche RH, van der Stappen JW, et al.: Genetic polymorphism 609C>T in NAD(P)H:quinoneoxidoreductase 1 enhances the risk of proximal colon cancer. J Hum Genet 59(7), 381–386, 2014. doi:10.1038/jhg.2014.38.
   PubMed Web of Science ®Google Scholar
• Clairmont A, Sies H, Ramachandran S, Lear JT, Smith AG, et al.: Association of NAD(P)H: quinoneoxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 20, 1235–1240, 1999. doi:10.1093/carcin/20.7.1235.
   PubMed Web of Science ®Google Scholar
• Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, et al.: Increased frequency of a null-allele for NAD(P)H: quinoneoxidoreductase in patients with urological malignancies. Pharmacogenetics 7(3), 235–239, 1997. doi:10.1097/00008571-199706000-00008.
   PubMedGoogle Scholar
• Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, et al.: NAD(P)H:quinoneoxidoreductase- dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 21, 1813–1819, 2000. doi:10.1093/carcin/21.10.1813.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hu J, and Zhong J: Meta-analysis of the NAD(P)H: quinine oxidoreductase 1 gene 609 C>T polymorphism with esophageal cancer risk. DNA Cell Biol 31, 560–567, 2012. doi:10.1089/dna.2011.1332.
   PubMed Web of Science ®Google Scholar
• Park SJ, Zhao H, Spitz MR, Grossman HB, and Wu X: An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 536(1–2), 131–137, 2003. doi:10.1016/S1383-5718(03)00041-X.
   PubMed Web of Science ®Google Scholar
• Guo ZJ, and Feng CL: The NQO1 rs1800566 polymorphism and risk of bladder cancer: evidence from 6,169 subjects. Asian Pac J Cancer Prev 13(12), 6343–6348, 2012. doi:10.7314/APJCP.2012.13.12.6343.
   PubMedGoogle Scholar
• Rosvold EA, McGlynn KA, Lustbader ED, and Buetow KH: Identification of an NAD(P)H: quinoneoxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5, 199–206, 1995. doi:10.1097/00008571-199508000-00003.
   PubMedGoogle Scholar
• Chen H, Lum A, Seifried A, Wilkens LR, and Marchand LL: Association of the NAD(P)H: quinoneoxidoreductase 609C3T polymorphism with a decreased lung cancer risk. Cancer Res 59, 3045–3048, 1999.
   PubMed Web of Science ®Google Scholar
• Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, et al.: Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62, 3052–3057, 2002.
   PubMed Web of Science ®Google Scholar
• Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, et al.: A lack of a functional NAD(P)H:quinoneoxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 59(16), 4095–4099, 1999.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Sinnett H, Richer C, Labuda D, and Sinnett D: Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 97(2), 230–236, 2002. doi:10.1002/ijc.1589.
   PubMed Web of Science ®Google Scholar
• Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JL, et al.: Low NAD(P)H:quinoneoxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97(5), 1422–1426, 2001. doi:10.1182/blood.V97.5.1422.
   PubMed Web of Science ®Google Scholar
• Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, et al.: Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6(10), 4091–4095, 2000.
   PubMed Web of Science ®Google Scholar
• Han FF, Guo CL, Gong LL, Jin Z, and Liu LH: Effects of the NQO1 609C>T polymorphism on leukemia susceptibility: evidence from a meta-analysis. Asian Pac J Cancer Prev 14(9), 5311–5316, 2013. doi:10.7314/APJCP.2013.14.9.5311.
   PubMedGoogle Scholar
• Iyanagi T, and Yamazaki I: One-electron-transfer reactions in biochemical systems. V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim Biophys Acta 216(2), 282–294, 1970.
   PubMed Web of Science ®Google Scholar
• Bianchet MA, Faig M, and Amzel LM: Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO). Methods Enzymol 382, 144–174, 2004. doi:10.1016/S0076-6879(04)82009-3.
   PubMed Web of Science ®Google Scholar
• Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, et al.: NAD(P)H:quinoneoxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 65(5), 1238–1247, 2004.
   PubMed Web of Science ®Google Scholar
• Wignall SM, Gray NS, Chang YT, Juarez L, Jacob R, et al.: Identification of a novel protein regulating microtubule stability through a chemical approach. Chem Biol 11(1), 135–146, 2004.
   PubMedGoogle Scholar
• Asher G, Lotem J, Kama R, Sachs L, and Shaul Y: NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 99(5), 3099–3104, 2002. doi:10.1073/pnas.052706799.
   PubMed Web of Science ®Google Scholar
• Asher G, Lotem J, Sachs L, Kahana C, and Shaul Y: Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci USA 99(20), 13125–13130, 2002. doi:10.1073/pnas.202480499.
   PubMed Web of Science ®Google Scholar
• Rai V: Polymorphism in folate metabolic pathway gene as maternal risk factor for Down syndrome. Int J Biol Med Res 2(4), 1055–1060, 2011.
   Google Scholar
• Rai V: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and alzheimer disease risk: a meta-analysis. Molecular Neurobiology 54, 1173–1186, 2016. doi:10.1007/s12035-016-9722-8.
   PubMed Web of Science ®Google Scholar
• Rai V: Methylenetetrahydrofolate reductase A1298C polymorphism and breast cancer risk: a meta-analysis of 33 studies. Ann Med Health Sciences Res 4(6), 841–851, 2014. doi:10.4103/2141-9248.144873.
   PubMedGoogle Scholar
• Yang FY, Guan QK, Cui YH, Zhao ZQ, Rao W, et al.: NAD(P)H quinoneoxidoreductase 1 (NQO1) genetic C609T polymorphism is associated with the risk of digestive tract cancer: a meta-analysis based on 21 case–control studies. Eur J Cancer Prev 21, 432–441, 2012. doi:10.1097/CEJ.0b013e32834f7514.
   PubMed Web of Science ®Google Scholar
• Yu H, Liu H, Wang LE, and Wei Q: A functional NQO1 609C>T polymorphism and risk of gastrointestinal cancers: a meta-analysis. PLoS One 7(1), e30566, 2012. doi:10.1371/journal.pone.0030566.
   PubMed Web of Science ®Google Scholar